Drawing for RHYGAZE

USPTO serial 79413712

RHYGAZE

Reviewed by CopyMark Law Group

Reg. 8155620Status 700Registered
Filing date
Status date
Registration date
Mar 3, 2026
Examiner
HUDSON, TAMARA BREE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with RHYGAZE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

James R Menker

James R Menker Holley & Menker, PA60 Ocean Boulevard, Suite 3Atlantic Beach, FL 32233United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and medical preparations, namely, ophthalmologic preparations; biological medical and pharmaceutical preparations for treating ophthalmologic conditions, ailments, diseases and disorders; Pharmaceutical and medical preparations for treating eye diseases; biological medical and pharmaceutical preparations for treating eye diseases; pharmaceutical and biological preparations for use in cell cultures for medical purposes, namely, nucleic acids, protein arrays, protein conjugates, synthetic peptides, attenuated viruses, viral vectors and viral constructions; biological tissue cultures for medical use; biological tissue cultures intended for medical use in the diagnosis, prevention and treatment of diseases, in particular eye diseases; biological tissue cultures intended for medical use in gene therapy treatments; pharmaceutical preparations for use in genetic-based therapies, namely, gene therapy preparations, gene-editing preparations, genome-editing preparations, and preparations incorporating CRISPR-based therapeutic agents for the treatment of eye diseases and other medical conditions; biological preparations comprising genetically modified cells, modified nucleic acids, viral and non-viral vectors for use in gene therapy and genome-editing medical treatments; all of the foregoing excluding preparations or other goods for the treatment of cancer and oncological diseases and disordersACTIVE—
042Scientific and technological services, namely, research and design services relating to gene therapy, genetic-based therapies, genome-editing technologies, CRISPR technologies, molecular biology, biotechnology, pharmacy and medicine; quality control for others and authentication of data in the field of medical records using blockchain technology; design and development of computers and software; research and development services in the fields of molecular biology, biotechnology, pharmacy and medicine; research and development services in the fields of molecular biology, biotechnology, pharmacy and medicine, in particular in the field of eye diseases; research and development services in the field of medical diagnostics, prophylaxis and therapy, in particular gene therapy; research services, namely, scientific examination and research of compounds and components intended for therapeutic or diagnostic use, in particular intended for use in relation to eye diseases; research services in the field of gene therapy; research and development in the fields of genome editing, CRISPR-based technologies, and genetic-engineering tools for medical and therapeutic use; scientific research for developing protocols, for technical planning, and for providing advice in the fields of molecular biology, biotechnology and pharmacy, in particular intended for use in the field of ocular diseases and gene therapiesACTIVE—
044Medical services; medical services, namely medical diagnosis through molecular biology, genetic engineering and biotechnology methods, in particular in the field of eye diseases; therapy services, in particular gene therapy for medical treatment purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 10, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 25, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 25, 2026FIMPFINAL DISPOSITION PROCESSED—
Jun 18, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jun 3, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 1, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
May 31, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Apr 6, 2026LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Mar 3, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Mar 3, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 13, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 13, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 7, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 16, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 15, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 15, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 15, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 26, 2025LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Jul 12, 2025RFNTREFUSAL PROCESSED BY IB—
Jun 20, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 20, 2025RFRRREFUSAL PROCESSED BY MPU—
Apr 17, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 16, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 9, 2025DOCKASSIGNED TO EXAMINER—
Jan 3, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 3, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 2, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance